Pay in 4 interest-free payments of $6.82 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
The trial enrolled 300 obese subjects (BMI 27-35 kg/m) across multiple centers and randomized them to AOD-9604 (3 mg subcutaneous injection once or twice daily) or placebo for 12 weeks
Tirzepatide has shown promising results in clinical trials, offering a new therapeutic option for those struggling to achieve glycemic control with existing treatments
Effective treatment of cobalamin deficiency with oral cobalamin
NICE-approved weight management interventions include: Dietary and lifestyle modification first-line approach for all patients Orlistat licensed medication for obesity (BMI 30 or 28 with comorbidities) GLP-1 receptor agonists including semaglutide (Wegovy) per NICE TA875 and liraglutide (Saxenda) with restrictions per NICE TA664, for specific patient groups Bariatric surgery for severe obesity meeting strict criteria The NHS emphasises that sustainable weight loss requires behavioural change, nutritional education, and increased physical activity
Telehealth pricing typically covers the vial only
US$ 27.63
US$ 26.43
US$ 24.70
US$ 27.72
